TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|119|24|4290-4298

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.24, 2013-12, pp. : 4290-4298

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 67-71

Karger

Access to resources Recommend Favorite

Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6

By  

Oncology, Vol. 79, Iss. 3-4, 2011-02 ,pp. : 174-180

Karger

Access to resources Recommend Favorite

5-Fluorouracil, Leucovorin and Oxaliplatin plus Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer: A Single-Institute Study

By  

Oncology, Vol. 72, Iss. 1-2, 2007-10 ,pp. : 4-9

Karger

Access to resources Recommend Favorite

Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701)

By  

Oncology, Vol. 84, Iss. 4, 2013-01 ,pp. : 233-239

Karger

Access to resources Recommend Favorite

Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

By  

Oncology, Vol. 92, Iss. 4, 2017-02 ,pp. : 205-212

Karger

Access to resources Recommend Favorite